SCYNEXIS, Inc. to Present at RBC Capital Markets 2015 Healthcare Conference

Download as PDF

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that Yves J. Ribeill, Ph.D., SCYNEXIS' CEO and President, will present at the RBC Capital Markets 2015 Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, February 24, 2015, at 3:05 p.m. ET.

A live webcast will be available on the investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for three months following the presentation.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

CONTACT: Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         E-mail: hsavelle@macbiocom.com

         Investor Relations
         Jillian Connell
         The Trout Group LLC
         Tel: 646.378.2956
         E-mail: jconnell@troutgroup.com

         SCYNEXIS, Inc.
         Chuck Osborne
         Chief Financial Officer
         Tel: 919.544.8600
         E-mail: chuck.osborne@scynexis.com
Source: SCYNEXIS, Inc.

Released February 19, 2015